Clovis Oncology (CLVS) Tops Q4 EPS by 6c

Clovis Oncology (NASDAQ: CLVS) reported Q4 EPS of ($0.50), $0.06 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $36 million versus the consensus estimate of $39.08 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• Analog Devices climbs as fiscal Q3 results, Q4 outlook beat forecasts